Effects of Tigecycline and Doxycycline on Inflammation and Hemodynamics in Porcine Endotoxemia: A Prospective, Randomized, and Placebo-Controlled Trial

Shock

Volumn 43, Issue 6, 2015, Pages 604-611

  Von Seth, Magnus ^a   Sjölin, Jan ^a   Larsson, Anders ^a   Eriksson, Mats ^a   Hillered, Lars ^a   Lipcsey, Miklós ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Animal models; doxycycline; endotoxins; nitric oxide; sepsis; swine; tigecycline; tumor necrosis factor

Indexed keywords

DOXYCYCLINE; ENDOTOXIN; NITRIC OXIDE; PLACEBO; TIGECYCLINE; TUMOR NECROSIS FACTOR ALPHA; MINOCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; ENDOTOXEMIA; HEMODYNAMICS; INFLAMMATION; LEUKOCYTE COUNT; MALE; MEAN ARTERIAL PRESSURE; METABOLITE; NEUTROPHIL COUNT; NONHUMAN; PIG; PROSPECTIVE STUDY; SEPSIS; TISSUE METABOLISM; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; RANDOMIZATION;

ANIMALS; DOXYCYCLINE; ENDOTOXEMIA; HEMODYNAMICS; INFLAMMATION; MALE; MINOCYCLINE; RANDOM ALLOCATION; SWINE;

EID: 84942985932     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000351     Document Type: Article

References (28)

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165-228, 2013.
2. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589-1596, 2006.
3. Kumar A, Safdar N, Kethireddy S, Chateau D: A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 38(8):1651-1664, 2010.
4. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, et al.: Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 38(9):1773-1785, 2010.
5. Schwaber MJ, Carmeli Y: Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chem 60(5): 913-920, 2007.
6. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D: Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34(2):344-353, 2006.
7. Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, Plachouras D, Kollias S, Raftogiannis M, Kopterides P, Lymberopoulou K, Mouktaroudi M, et al.: Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 46(8):1157-1164, 2008.
8. Kielian T, Esen N, Liu S, Phulwani NK, Syed MM, Phillips N, Nishina K, Cheung AL, Schwartzman JD, Ruhe JJ: Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess. Am J Pathol 171(4):1199-1214, 2007.
9. Krakauer T, Buckley M: Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 47(11):3630-3633, 2003.
10. Maitra SR, Bhaduri S, Chen E, Shapiro MJ: Role of chemically modified tetracycline on TNF-alpha and mitogen-activated protein kinases in sepsis. Shock (Augusta, Ga) 22(5):478-481, 2004.
11. Meloni F, Ballabio P, Bianchi L, Grassi FA, Gialdroni Grassi GG: Cefodizime modulates in vitro tumor necrosis factor-alpha, interleukin-6 and interleukin-8 release from human peripheral monocytes. Chemotherapy 41(4):289-295, 1995.
12. Steinberg J, Halter J, Schiller H, Gatto L, Carney D, Lee HM, Golub L, Niemam G: Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock (Augusta, Ga) 24(4):348-356, 2005.
13. Tkalcevic VI, Hrvacic B, Pasalic I, Erakovic Haber V, Glojnaric I: Immunomodulatory effects of azithromycin on serum amyloid A production in lipopolysaccharide-induced endotoxemia in mice. J Antibiot (Tokyo) 64(7): 515-517, 2011.
14. Topsakal C, Kilic N, Ozveren F, Akdemir I, Kaplan M, Tiftikci M, Gursu F: Effects of prostaglandin E1, melatonin, and oxytetracycline on lipid peroxidation, antioxidant defense system, paraoxonase (PON1) activities, and homocysteine levels in an animal model of spinal cord injury. Spine 28(15): 1643-1652, 2003.
15. Duran WN, Breslin JW, Sanchez FA: The NO cascade, eNOS location, and microvascular permeability. Cardiovasc Res 87(2):254-261, 2010.
16. Mian AI, Aranke M, Bryan NS: Nitric oxide and its metabolites in the critical phase of illness: rapid biomarkers in the making. Open Biochem J 7:24-32, 2013.
17. Villalpando S, Gopal J, Balasubramanyam A, Bandi VP, Guntupalli K, Jahoor F: In vivo arginine production and intravascular nitric oxide synthesis in hypotensive sepsis. Am J Clin Nutr 84(1):197-203, 2006.
18. Dunston CR, Griffiths HR, Lambert PA, Staddon S, Vernallis AB: Proteomic analysis of the anti-inflammatory action of minocycline. Proteomics 11(1): 42-51, 2011.
19. Goscinski G, Lipcsey M, Eriksson M, Larsson A, Tano E, Sjolin J: Endotoxin neutralization and anti-inflammatory effects of tobramycin and ceftazidime in porcine endotoxin shock. Crit Care (London, England) 8(1):R35YR41, 2004.
20. Garcia RA, Pantazatos DP, Gessner CR, Go KV, Woods VL Jr., Villarreal FJ: Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry. Mol Pharmacol 67(4):1128-1136, 2005.
21. da Silva LM, Nunes Salgado HR: Tigecycline: a review of properties, applications, and analytical methods. Ther Drug Monit 32(3):282-288, 2010.
22. Salvatore CM, Techasaensiri C, Tagliabue C, Katz K, Leos N, Gomez AM, et al.: Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 53(4): 1546-1551, 2009.
23. Naess A, Andreeva H, Sornes S: Tigecycline attenuates polymorphonuclear leukocyte (PMN) receptors but not functions. Acta Pharm 61(3): 297-302, 2011.
24. Traunmuller F, Thallinger C, Hausdorfer J, Lambers C, Tzaneva S, Kampitsch T, Endler G, Joukhadar C: Tigecycline has no effect on cytokine release in an ex vivo endotoxin model of human whole blood. Int J Antimicrob Agents 33(6):583-586, 2009.
25. Kissoon N, Orr RA, Carcillo JA: Updated American College of Critical Care Medicine pediatric advanced life support guidelines for management of pediatric and neonatal septic shock: relevance to the emergency care clinician. Pediatr Emerg Care 26(11):867-869, 2010.
26. Dodds WJ, Abelseth MK: Criteria for selecting the animal to meet the research need. Lab Anim Sci 30(2 Pt 2):460-465, 1980.
27. Koff WC, Fann AV, Dunegan MA, Lachman LB. Catecholamine-induced suppression of interleukin-1 production. Lymphokine Res 5(4):239-247, 1986.
28. Riond JL, Riviere JE: Pharmacokinetics and metabolic inertness of doxycycline in young pigs. Am J Vet Res 51(8):1271-1275, 1990.